Hemostats Market (By Product: Passive Hemostats, Combination Hemostats, Active Hemostats, Others; By Application: Plastic Surgery, Orthopedic Surgery, Trauma, Cardiovascular Surgery, General Surgery, Neurosurgery, Others; By End-User: Tactical Combat Casualty Care Centers, Hospitals & ASCs, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
The global hemostats market size is projected to hit around USD 10.07 billion by 2032 from USD 5.08 billion in 2023 and is growing at a CAGR of 7.90% during the forecast period from 2023 to 2032.
The U.S. hemostats market size was valued at USD 1.21 billion in 2023 and is expected to reach USD 2.37 billion by 2032, poised to grow at a CAGR of 7.80% from 2023 to 2032.
North America has held the largest revenue share of 34% in 2022. This is due to the region's advancing healthcare, ensuring patient safety, and promoting surgical precision. It also signifies the region's role as a hub for medical device innovation, with a strong emphasis on research and development in the healthcare sector. The region is home to many leading medical device manufacturers and research institutions, fostering innovation in hemostatic products and their adoption in clinical practice. For instance, in January 2023, the U.S. Food and Drug Administration (FDA) granted the Breakthrough Device Designation for Medcura, Inc.’s LifeGel Absorbable Surgical Hemostat.
Asia Pacific is estimated to observe the fastest expansion. The region is growing its role in the global healthcare landscape and commitment to improving patient care, surgical outcomes, and emergency medical response, making it a vital part of the evolving healthcare ecosystem. Efforts to improve access to healthcare and reduce disparities in healthcare delivery are leading to a greater number of patients undergoing surgical procedures and trauma care, further driving the demand for the hemostats market across the region.
The hemostats market in Europe is a dynamic and evolving segment of the healthcare industry. Europe is known for its well-established healthcare systems, advanced medical technologies, and a strong focus on patient safety. Thus, the hemostats market in Europe reflects a region committed to providing advanced healthcare services with a strong emphasis on patient care, safety, and surgical precision. It continues to be a key player in the global healthcare landscape.
Hemostats Market Overview
Hemostats, also known as hemostatic forceps or arterial forceps, are surgical instruments used to control bleeding during surgical procedures or to grasp and hold tissues or blood vessels. They are designed to provide a secure and temporary method of clamping blood vessels or tissues to prevent excessive bleeding. Hemostats have a locking mechanism that allows the surgeon to maintain a constant level of pressure on the tissue or vessel, which is especially important when working in delicate or sensitive areas of the body.
The hemostats market encompasses a variety of hemostatic agents and tools designed to control bleeding in medical and surgical settings. The hemostats market is driven by various factors, including the increasing number of surgical procedures, the aging population, and ongoing advancements in medical technology. Hemostatic products are crucial in reducing blood loss during surgeries, which helps enhance patient outcomes and minimize the risk of complications. They find application in a broad range of medical disciplines, such as general surgery, orthopedics, cardiovascular surgery, and trauma care.
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 7.90% |
| Market Size in 2023 | USD 5.08 Billion |
| Market Size by 2032 | USD 10.07 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product, By Application, By End-User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver
Rising number of surgical interventions
The incidence of surgical procedures continues to climb as global demographics change and populations grow. Several factors such as an aging population that involves more medical attention, a surge in the prevalence of chronic diseases requiring surgical interventions, and the development of surgical techniques and technologies. In precise, the expanding middle-class population in emerging economies has resulted in greater access to healthcare and a surge in elective surgeries. Their ability to effectively control bleeding during surgeries is paramount to ensure safe and successful procedures. Thus, these factors further drive demand across the market.
In addition, surgeons across numerous specialties rely on hemostatic devices and agents to reduce blood loss, increase surgical precision, and decrease the risk of complications. Hemostats are indispensable in a wide range of surgeries, including general surgery, orthopedics, cardiovascular surgery, and trauma care. Furthermore, as medical advancements continue, the hemostats market benefits from ongoing innovation, the development of more user-friendly products, and the integration of advanced materials and technologies. The rising demand for surgical interventions, coupled with the importance of effective bleeding control, positions the hemostats market for sustained growth and a central role in the enhancement of patient care and surgical outcomes in the years to come.
Restraint
Limited access in developing regions
Thermostat agents and devices play a crucial role in modern healthcare, their reach remains limited in many parts of the world, particularly in underserved and developing regions. One primary issue is the lack of adequate healthcare infrastructure, which affects the availability of surgical services and the necessary tools, including hemostatic products. In remote and economically disadvantaged areas, healthcare facilities may be limited in number and resources, making it difficult for patients to access necessary surgical care.
Furthermore, in many developing regions, there is a shortage of trained healthcare professionals who can effectively utilize hemostatic agents and devices. This lack of expertise and awareness about these advanced medical tools can hinder their adoption. Economic factors also need to be considered. In regions with limited healthcare budgets and resources, the cost of acquiring hemostatic products may be prohibitive.
Manufacturers often face challenges in making their products affordable and accessible to healthcare institutions in these areas. The limitations in supply chain and distribution networks can further impede access to hemostatic products. Ensuring the timely and efficient delivery of these critical medical tools to remote and underserved regions can be logistically challenging.
Opportunity
Continued innovations in hemostats agents
The development of more advanced and effective hemostatic products plays a pivotal role in enhancing patient care, improving surgical outcomes, and reducing complications in a wide range of medical procedures. In the realm of hemostatic agents, manufacturers are continually exploring new formulations, materials, and technologies to create products that offer faster and more reliable hemostasis while minimizing the risk of adverse reactions. Innovations in these agents can lead to improved clotting efficacy and enhanced safety, ultimately benefiting patients and healthcare providers.
Moreover, the design and engineering of hemostatic devices are evolving to meet the changing demands of modern medicine. With the growth of minimally invasive surgery and the demand for precision in surgical procedures, the development of specialized devices tailored to these applications is a prominent opportunity. These innovations aim to improve usability, reduce complications, and streamline the hemostatic process. In addition, the integration of smart technologies and real-time monitoring in hemostatic products offers promising prospects.
Such advancements can provide healthcare professionals with valuable data on clotting status, wound healing, and patient vitals, enabling more informed decision-making and personalized care. As healthcare continues to advance, innovations in hemostatic agents and devices will play a vital role in ensuring that surgeries are safer, more efficient, and produce optimal patient outcomes.
According to the application, the general surgery segment has held highest revenue share in 2022. General surgery encompasses a broad range of procedures involving the abdomen, digestive system, and other organs. Hemostats are used to control bleeding in surgeries such as appendectomies, gallbladder removal, and hernia repairs.
The ability to achieve effective hemostasis is vital in these operations, as it contributes to reduced blood loss, shorter operating times, and decreased post-operative complications. The dominance of the general surgery segment reflects the demand for reliable, safe, and efficient solutions that healthcare providers and surgeons depend on to ensure the success and safety of general surgical interventions.
The cardiovascular surgery segment is anticipated to expand fastest over the projected period. Cardiovascular surgery is a specialized field that involves intricate procedures on the heart and blood vessels, often with minimal room for error. In heart and vascular surgeries, precise hemostasis is critical to ensure the repair or replacement of heart valves, coronary artery bypass grafting, or other procedures without complications related to bleeding.
In 2022, the active hemostats segment had the highest market share on the basis of the product. Active hemostats are products that contain biologically active substances or synthetic agents designed to enhance the body's natural clotting processes. These substances may include thrombin, fibrin sealants, or other clot-promoting factors. Active hemostats accelerate the clotting of blood and promote hemostasis. Thus, these factors drive demand for hemostats market across the segment.
The combination hemostats segment is anticipated to expand fastest over the projected period. This is due to these products offering a dual approach, utilizing mechanical methods to control bleeding while also promoting clot formation through the use of biologically active substances. Combination hemostats are products that incorporate both active and passive components to achieve hemostasis.
In 2022, the hospitals & ASCs segment had the highest market share based on the end-user. Hospitals and ambulatory surgical centers are primary users of hemostatic agents and devices. Hemostats are extensively used in these settings across a wide range of medical specialties, including general surgery, orthopedics, cardiovascular surgery, trauma care, and more. They play a crucial role in controlling bleeding during surgical procedures and ensuring patient safety.
The others segment is anticipated to expand fastest over the projected period. The other segment usually includes other healthcare institutions, clinics, and healthcare providers that use hemostatic agents and devices to ensure that solutions are available and optimized for various clinical contexts, ultimately contributing to improved patient care, surgical outcomes, and emergency medical response. These could encompass specialty clinics, outpatient surgical facilities, dental clinics, and others.
Segments Covered in the Report
By Product
By Application
By End-User
By Geography
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Access TOC
Get a Sample